Syndax Pharmaceuticals Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 2.17
Dividend & YieldN/A$ (N/A)
Beta 1.11
Market capitalization 1.34B
Operating cash flow -10.07M
ESG Scores unknown

Company description

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.

Sector: Healthcare - Industry: Biotechnology

Financial Ratios
Quick Ratio21.68
Working Capital0.06
Return On Equity0.06
Debt To Equity0.05
Fixed Asset Ratio0.99
Fixed Interest Cover13.81

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -2.31M 3.22M -4.19M -10.97M
Total Cashflows From Investing Activities 51.4M 12.78M -142.53M -40.87M
Net Borrowings 19.73M 19.73M 19.73M
Total Cash From Financing Activities 15.73M 28.57M 304.42M 118.46M
Change To Operating Activities 2.01M -3.46M -3.75M 1.38M
Issuance Of Stock 15.72M 28.57M 284.69M 117.89M
Net Income -73.96M -56.05M -73.16M 24.93M
Change In Cash -1.4M -9.26M 90.63M 106.72M
Effect Of Exchange Rate
Total Cash From Operating Activities -68.53M -50.61M -71.26M 29.13M
Depreciation 78k 92k 89k 43k
Change To Account Receivables
Other Cashflows From Financing Activities 8k 1k 1k 576k
Change To Netincome 5.65M 5.58M 9.74M 13.76M
Capital Expenditures -187k -129k -129k -129k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 60.11M 42.99M 50.44M 88.25M
Income Before Tax -73.96M -56.05M -73.16M 24.93M
Net Income -73.96M -56.05M -73.16M 24.93M
Selling General Administrative 17.29M 16.06M 22.5M 25.24M
Gross Profit 1.52M 1.52M 1.52M 139.71M
Ebit -75.88M -57.54M -71.42M 26.22M
Operating Income -75.88M -57.54M -71.42M 26.22M
Interest Expense -2.36M -2.36M -2.36M -1.9M
Income Tax Expense
Total Revenue 1.52M 1.52M 1.52M 139.71M
Cost Of Revenue
Total Other Income ExpenseNet 1.92M 1.49M -1.74M -1.29M
Net Income From Continuing Ops -73.96M -56.05M -73.16M 24.93M
Net Income Applicable To Common Shares -73.96M -56.05M -77.06M 24.93M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 30.89M 31.93M 48.42M 41.29M
Total Stockholder Equity 53.05M 31.6M 252.19M 408.37M
Other Current Liabilities 1.52M 1.52M 1.52M 187k
Total Assets 83.94M 63.52M 300.61M 449.66M
Common Stock 2k 3k 5k 6k
Other Current Assets 433k 347k 432k 495k
Retained Earnings -439.42M -495.47M -568.63M -543.7M
Treasury Stock -25k -4k 45k
Cash 33.77M 24.61M 115.24M 221.97M
Total Current Liabilities 16.11M 18.37M 18.87M 20.68M
Other Stockholder Equity -25k -4k 45k
Property, Plant, and Equipment 373k 997k 482k 1.26M
Total Current Assets 83.35M 62.33M 298.86M 448.4M
Net Tangible Assets 53.05M 31.6M 252.19M 408.37M
Net Receivables 1.05M 532k 199k 429k
Accounts Payable 1.44M 6.18M 3.51M 5.67M


Insider Transactions

Here are the insider transactions of stock shares related to Syndax Pharmaceuticals Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
KATKIN KEITH ASale at price 25.90 per share.D2022-10-06Director29.9k
KATKIN KEITH AConversion of Exercise of derivative security at price 7.88 - 8.93 per share.D2022-10-06Director29.9k
METZGER MICHAEL ASale at price 25.29 per share.D2022-10-06Chief Executive Officer16.23k
METZGER MICHAEL AConversion of Exercise of derivative security at price 8.77 per share.D2022-10-06Chief Executive Officer16.23k
KATKIN KEITH ASale at price 25.00 - 25.07 per share.D2022-10-04Director4.1k
KATKIN KEITH AConversion of Exercise of derivative security at price 7.88 - 8.93 per share.D2022-10-04Director4.1k
METZGER MICHAEL ASale at price 25.01 - 25.02 per share.D2022-10-04Chief Executive Officer33.77k
METZGER MICHAEL AConversion of Exercise of derivative security at price 8.77 per share.D2022-10-04Chief Executive Officer33.77k
MORRISON BRIGGS WSale at price 23.03 - 23.25 per share.D2022-09-20Officer and Director173.99k
MORRISON BRIGGS WConversion of Exercise of derivative security at price 10.90 per share.D2022-09-20Officer and Director173.99k
PODLESAK DENNIS GSale at price 23.43 - 24.20 per share.D2022-09-16Director78.81k
PODLESAK DENNIS GConversion of Exercise of derivative security at price 6.32 - 6.35 per share.D2022-09-16Director78.81k
MORRISON BRIGGS WSale at price 23.22 - 24.20 per share.D2022-09-16Officer and Director279.42k
MORRISON BRIGGS WConversion of Exercise of derivative security at price 7.20 - 10.90 per share.D2022-09-16Officer and Director279.42k
ORDENTLICH PETER PH.D.Sale at price 25.04 per share.D2022-08-24Officer25k
ORDENTLICH PETER PH.D.Conversion of Exercise of derivative security at price 6.32 - 6.35 per share.D2022-08-24Officer25k
LEGAULT PIERRESale at price 23.02 per share.D2022-08-05Director24k
LEGAULT PIERREConversion of Exercise of derivative security at price 8.93 - 9.63 per share.D2022-08-05Director24k
METZGER MICHAEL ASale at price 21.06 per share.D2022-07-25Chief Executive Officer31.6k
METZGER MICHAEL AConversion of Exercise of derivative security at price 6.38 per share.D2022-07-25Chief Executive Officer31.6k
METZGER MICHAEL ASale at price 21.00 - 21.07 per share.D2022-07-07Chief Executive Officer15.11k
METZGER MICHAEL AConversion of Exercise of derivative security at price 6.38 per share.D2022-07-07Chief Executive Officer15.11k
MORRISON BRIGGS WSale at price 19.00 per share.D2022-07-01President62.29k
MORRISON BRIGGS WConversion of Exercise of derivative security at price 7.20 per share.D2022-07-01President62.29k
GOLDAN KEITH AStock Award(Grant) at price 0.00 per share.D2022-06-13Chief Financial Officer3.21k
MORRISON BRIGGS WSale at price 17.44 - 18.29 per share.D2022-04-04Officer and Director104.17k
MORRISON BRIGGS WConversion of Exercise of derivative security at price 7.20 per share.D2022-04-04Officer and Director73.67k
PODLESAK DENNIS GStock Award(Grant) at price 0.00 per share.D2022-02-02Director32k
KATKIN KEITH AStock Award(Grant) at price 0.00 per share.D2022-02-02Director16k
LEGAULT PIERREStock Award(Grant) at price 0.00 per share.D2022-02-02Director16k
MEURY WILLIAMStock Award(Grant) at price 0.00 per share.D2022-02-02Director16k
HUBER MARTIN H JRStock Award(Grant) at price 0.00 per share.D2022-02-02Director16k
EGROS FABRICEStock Award(Grant) at price 0.00 per share.D2022-02-02Director16k
JARRETT JENNIFERStock Award(Grant) at price 0.00 per share.D2022-02-02Director16k
ORDENTLICH PETER PH.D.Sale at price 16.65 per share.D2022-02-01Officer1.41k
NOLTE ALEXANDERSale at price 16.65 per share.D2022-02-01Officer968
MEYERS MICHAEL LConversion of Exercise of derivative security at price 8.77 per share.D2021-12-30Officer5.9k
LEGAULT PIERRESale at price 21.01 - 22.01 per share.D2021-12-22Director44k
LEGAULT PIERREConversion of Exercise of derivative security at price 7.08 - 7.88 per share.D2021-12-22Director44k
METZGER MICHAEL ASale at price 19.02 - 20.29 per share.D2021-12-20President85.39k
METZGER MICHAEL AConversion of Exercise of derivative security at price 6.38 - 8.77 per share.D2021-12-20President85.39k
MORRISON BRIGGS WSale at price 20.00 per share.D2021-12-17Chief Executive Officer35.16k
MORRISON BRIGGS WConversion of Exercise of derivative security at price 10.90 per share.D2021-12-17Chief Executive Officer35.16k
METZGER MICHAEL ASale at price 19.05 per share.D2021-12-13President36.61k
METZGER MICHAEL AConversion of Exercise of derivative security at price 6.38 - 7.20 per share.D2021-12-13President36.61k
EGROS FABRICESale at price 18.03 per share.D2021-11-18Director14.03k
EGROS FABRICEConversion of Exercise of derivative security at price 7.88 - 8.93 per share.D2021-11-18Director14.03k
METZGER MICHAEL ASale at price 19.13 - 19.20 per share.D2021-10-26President61k
METZGER MICHAEL AConversion of Exercise of derivative security at price 7.20 per share.D2021-10-26President61k
METZGER MICHAEL ASale at price 19.51 per share.D2021-09-27President24.44k
METZGER MICHAEL AConversion of Exercise of derivative security at price 7.20 per share.D2021-09-27President24.44k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Syndax Pharmaceuticals Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Syndax Pharmaceuticals Inc

Here is the result of two systematic investment strategies applied to Syndax Pharmaceuticals Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Syndax Pharmaceuticals Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Syndax Pharmaceuticals Inc:

Syndax Pharmaceuticals Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 77.85% on the backtest period.

Performance at glance

Performance

77.85 %

Latent gain

1736.39 $

Invested capital

2230.41 $

Annualized return

18.8 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Syndax Pharmaceuticals Inc

This is the result of two momentum investment strategies applied to Syndax Pharmaceuticals Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Syndax Pharmaceuticals Inc

The following chart shows all the entries opened by the momentum investment system on Syndax Pharmaceuticals Inc:

Syndax Pharmaceuticals Inc momentum entries
  • The first momentum investment strategy would give 116.56% of return on Syndax Pharmaceuticals Inc. That represents 5555.27$ of latent gain with 4765.93$ of employed capital.
  • The second momentum investment strategy would give 118.21% of return on Syndax Pharmaceuticals Inc. That represents 4430.21$ of latent gain with 3747.79$ of employed capital.
Performance at glance (1Q Momentum)

Performance

116.56 %

Latent gain

5555.27 $

Invested capital

4765.93 $

Annualized return

-2.89 %
Performance at glance (2Q Momentum)

Performance

118.21 %

Latent gain

4430.21 $

Invested capital

3747.79 $

Annualized return

32.3 %

Momentum equity curve on Syndax Pharmaceuticals Inc

The following chart shows the equity curve of the two momentum strategies applied to Syndax Pharmaceuticals Inc:

Syndax Pharmaceuticals Inc momentum equity

Note: the dividends potentially given by Syndax Pharmaceuticals Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Syndax Pharmaceuticals Inc

The following chart shows the employed capital evolution of the two momentum strategies on Syndax Pharmaceuticals Inc since the beginning:

Syndax Pharmaceuticals Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Syndax Pharmaceuticals Inc

Buy the dip entry openings on Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

The performance achieved by the robo-advisor on Syndax Pharmaceuticals Inc is -6.19%. That represents -14.88$ of latent gain with 240.48$ of employed capital. The following chart shows Syndax Pharmaceuticals Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Syndax Pharmaceuticals Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

-6.19 %

Latent gain

-14.88 $

Invested capital

240.48 $

Annualized return

-2.89 %

Equity curve of the strategy applied to Syndax Pharmaceuticals Inc

The following chart shows the result of the investment strategy applied to Syndax Pharmaceuticals Inc:

Syndax Pharmaceuticals Inc

Note: the dividends potentially given by Syndax Pharmaceuticals Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Syndax Pharmaceuticals Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Syndax Pharmaceuticals Inc:

Syndax Pharmaceuticals Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Syndax Pharmaceuticals Inc

In this section, I will compare the three previous investment strategies applied to Syndax Pharmaceuticals Inc.

Equity curve comparison on Syndax Pharmaceuticals Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Syndax Pharmaceuticals Inc investment strategy comparison

Employed capital comparison on Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc investment comparison

Performance comparison on Syndax Pharmaceuticals Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 77.85% 1736.39$ 2230.41$ 18.8%
Momentum 1 quarter 116.56% 5555.27$ 4765.93$ 29.89%
Momentum 2 quarters 118.21% 4430.21$ 3747.79$ 32.3%
Non-directional -6.19% -14.88$ 240.48$ -2.89%
Annualized return comparison

Automatic investment

18.8 %

Momentum 1Q

32.3 %

Momentum 2Q

32.3 %

Non-directional

-2.89 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Syndax Pharmaceuticals Inc:

Note: The algorithm computes the probability of correlation between Syndax Pharmaceuticals Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Syndax Pharmaceuticals Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name Syndax Pharmaceuticals Inc
Country United States
City Waltham
Address 35 Gatehouse Drive
Phone 781 419 1400
Website www.syndax.com
FullTime employees 59
Industry Biotechnology
Sector Healthcare
Exchange XNAS
Ticker SNDX
Market www.nasdaq.com

Syndax Pharmaceuticals Inc ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown